Clinical trials: psoriasis
Psoriasis Vulgaris
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
The objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 16 years and 11 months…
- Trial name
- NCT02125279
- Testing
- Calcitriol
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 54 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
- Trial name
- NCT03210961
- Testing
- PF-06826647 tablet, PF-06826647 oral suspension
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psoriatic Arthritis
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3…
- Trial name
- INVIGORATE 2 (NCT04209205)
- Testing
- AIN457 6 mg/kg i.v., AIN457 3 mg/kg
- Where
- 80 sites in United States, Brazil and 13 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris
A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
The purpose of the study is to evaluate the anti-psoriatic effect of LEO 90100 cutaneous spray ointment, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.
- Trial name
- NCT01347255
- Testing
- LEO90100 cutaneous spray, ointment, LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate, LEO 90100 cutaneous spray, ointment, vehicle
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Moderate to Severe Psoriasis
Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis
To compare the efficacy of ETN 50mg twice weekly for 12 weeks followed by reduction to a maintenance dose of 25mg twice weekly at week 24 with that of combination of ETN 25 mg Twice Weekly plus Acitretin 10mg BID at week 24 in…
- Trial name
- NCT00936065
- Testing
- Etanercept, Etanercept + Acitretin, Acitretin
- Where
- 10 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Pfizer
Pediatric Plaque Psoriasis
Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis
The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe psoriasis.
- Trial name
- NCT00141921
- Testing
- Etanercept
- Volunteers
- 182 people
- Sponsor
- Amgen
Psoriasis
Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.
- Trial name
- NCT03135548
- Testing
- Spesolimab (low dose), Spesolimab (high dose)
- Where
- 18 sites in Canada, Denmark and 4 more
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Generalized Pustular Psoriasis
An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
This Expanded Access trial in Japan is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP). This program provides a medicine called spesolimab to people with a GPP flare-up who have no…
- Trial name
- NCT05200247
- Testing
- spesolimab
- Where
- 9 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Boehringer Ingelheim
Psoriatic Nail, Psoriasis Vulgaris
A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
Psoriasis vulgaris is a common inflammatory condition of the skin that results in scaly red itchy plaques. In addition to affecting the skin, psoriasis can also cause disease in the finger and toe nails.
- Conditions
- Psoriatic Nail, Psoriasis Vulgaris, Psoriasis
- Trial name
- NCT03022617
- Testing
- Apremilast
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Candidates for Systemic Therapy for Psoriasis, Psoriasis
A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
An open-label, multi-center study to establish psoriasis control of moderate to severe plaque psoriasis with Raptiva therapy administered subcutaneously for 24 weeks.
- Trial name
- NCT00287118
- Testing
- Efalizumab
- Where
- Switzerland
- Volunteers
- 189 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
This is a randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of PPC-06 (tepilamide fumarate) extended release in subjects with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03421197
- Testing
- PPC-06 400 mg QD, PPC-06 400 mg BID, PPC-06 600 mg
- Where
- 74 sites in United States
- Volunteers
- 426 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- ERASURE (NCT01365455)
- Testing
- secukinumab 150 mg
- Where
- 88 sites in United States, Argentina and 10 more
- Volunteers
- 738 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
The main aim of this study is to assess treatment satisfaction, quality of life, treatment preference, adherence and convenience, psychosocial effects of scalp psoriasis, sleep quality, and effectiveness, and safety of…
- Trial name
- PRO-SCALP (NCT05811234)
- Testing
- CAL/BDP PAD Cream
- Where
- 37 sites in Germany, Spain and 1 more
- Volunteers
- 291 people
- Sponsor
- Almirall, S.A.
Palmoplantar Psoriasis
Safety and Efficacy of Infliximab in Palmoplantar Psoriasis
Palmoplantar psoriasis is a variant of psoriasis affecting palms and soles. It is one of the most debilitating variants of psoriasis which very often interferes with daily activities and with the ability to work.
- Trial name
- NCT00629772
- Testing
- Infliximab
- Where
- 5 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Innovaderm Research Inc.
Psoriasis Vulgaris, Psoriasis Arthropathica
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under…
- Conditions
- Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
- Trial name
- NCT03885089
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Pfizer
Psoriasis
Collaborative Connected Health (CCH) for PCORI
The investigators propose to evaluate whether an innovative collaborative connected health (CCH) model increases access to specialists and improves patient outcomes.
- Trial name
- PCORI (NCT02358135)
- Testing
- Collaborative Connected health, (CCH), Control
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Psoriasis, Plaque Psoriasis
A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)
This is a within-participant comparison study to investigate the efficacy of a 28-day regimen of MK-0873 2% cream twice a day (b.i.d.) compared to MK-0873 vehicle (matching placebo) b.i.d.
- Trial name
- NCT01235728
- Testing
- MK-0873 2% Cream, Calcitriol Cream
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life
This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years.
- Trial name
- NCT01169987
- Volunteers
- 191 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Plaque Psoriasis
ChangE From Any Systemic psoriasiS therapY to Raptiva
To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose.
- Trial name
- EASY (NCT00697593)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis Vulgaris
LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris
The purpose of this study is to investigate whether LEO 90100 and calcipotriol plus betamethasone are effective in the treatment of psoriasis vulgaris.
- Trial name
- NCT01536886
- Testing
- LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle
- Where
- 39 sites in United States
- Volunteers
- 376 people
- Sponsor
- LEO Pharma